IMPACT Therapeutics, Inc. (IMPACT THERAP-B) reported no changes to its authorised or issued share capital for the month ended 30 September 2026, according to the company’s latest Monthly Return filed with Hong Kong Exchanges and Clearing Limited on 5 October 2026.

The biotechnology firm’s authorised and registered H-share capital remained at 282.46 million shares, each with a par value of RMB 1, keeping total authorised capital unchanged at RMB 282.46 million. Issued shares also held steady at 282.46 million, with no treasury shares outstanding.

The filing confirms that IMPACT Therapeutics continues to meet the Main Board’s minimum public-float requirement of 25 percent of issued shares.

No share options, warrants, convertible securities, or other equity-linked instruments were issued, exercised, converted, or cancelled during the month, and there were no repurchases, redemptions, or movements in treasury shares.

The disclosure was signed by Executive Director and Chief Executive Officer Dr. Sui Xiong Cai.